Linezan (Linezolid)

Linezolid is used to treat bacterial infections affecting the skin, lungs and resistant Gram‑positive organisms.

• Complicated skin and soft tissue infections: achieves clinical cure and microbiological eradication in patients with severe cellulitis or wound infections.
• Community‑acquired and nosocomial pneumonia: helps eradicate the causative pathogens and improve respiratory outcomes.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides effective antibacterial activity against MRSA strains.
• Vancomycin‑resistant Enterococcus (VRE) infections: offers a treatment option for infections caused by VRE.

• Linezolid binds to the 23S ribosomal RNA of the bacterial 50S ribosomal subunit, preventing formation of the initiation complex required for protein synthesis. By selectively inhibiting the early stage of translation, it stops bacterial growth without affecting human cytoplasmic ribosomes, resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms. It retains activity against strains that produce certain resistance enzymes, making it useful for multidrug‑resistant infections.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset that may be transient.
• Diarrhea: loose stools that can range from mild to watery.
• Headache: dull or throbbing pain often relieved with rest.
• Vomiting: occasional expulsion of stomach contents.
• Metallic taste: transient alteration in taste perception.
• Rash: mild skin redness or itching.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count, increasing bleeding risk.
• Anemia: reduction in red blood cells leading to fatigue.
• Peripheral neuropathy: tingling or numbness in extremities.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
• Lactic acidosis: buildup of lactic acid causing metabolic disturbance.
• Optic neuropathy: visual disturbances due to optic nerve involvement.

When using Linezan, several safety considerations should be observed to minimize risks.

• Monitor blood counts: regular CBC testing is recommended to detect thrombocytopenia or anemia.
• Assess serotonergic medication use: avoid concomitant MAO inhibitors or SSRIs to reduce serotonin syndrome risk.
• Evaluate renal and hepatic function: dose adjustment may be needed in severe impairment.
• Use caution in patients with prior myelosuppression: increased susceptibility to hematologic adverse events.
• Avoid in individuals with known hypersensitivity to linezolid or other oxazolidinones: discontinue if allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezan can interact with other medicines, and interactions are classified by their clinical significance.

Major Interactions (Avoid)

• MAO inhibitors: may cause hypertensive crisis when combined.
• Serotonergic agents (SSRIs, SNRIs, tramadol): risk of serotonin syndrome.
• Rifampin: induces metabolism, markedly reducing linezolid exposure.
• Concomitant myelosuppressive drugs: additive risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase bleeding tendency.
• Anticoagulants (warfarin): potential enhancement of anticoagulant effect.
• Anticonvulsants (phenytoin, carbamazepine): may modestly lower linezolid levels.
• Oral contraceptives: possible reduction in efficacy, advise alternative contraception.